Page last updated: 22 April 2016

Post-market Review of Pulmonary Arterial Hypertension (PAH) Medicines


Post-market Review of biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) to treat Severe Chronic Plaque Psoriasis


Review of Pharmacy Remuneration and Regulation


Post-market Review of Chronic Obstructive Pulmonary Disease (COPD) Medicines


Post-market Review of Ezetimibe


Pharmaceutical Benefits Advisory Committee Guidelines Review


Post-market Reviews of Pharmaceutical Benefits Scheme Subsidised Medicines

The Government has introduced a systematic post-market approach to monitoring medicines in use to inform decision making at all levels throughout the medicine cycle (from the registration of a medicine right through to its use by consumers). More information can be found at:


Post-market Review of Authority Required Pharmaceutical Benefits Scheme Listings


Post-market Review of the Life Saving Drugs Programme


Post-market Review of Pharmaceutical Benefits Scheme Medicines to Treat Asthma in Children

Top of page


Post-market Review of Products Used in the Management of Diabetes


Post-market Review of Pharmaceutical Benefits Scheme anti-dementia drugs to treat Alzheimers Disease


Review of Anticoagulation Therapies in Atrial Fibrillation


12 Month Review of the Introduction of Streamlined Authorities

The report on the review of the first 12 months of operations of the PBS Streamlined Authorities, which were introduced to reduce the administrative burden for prescribers and allow them more time to devote to patient care.


Independent Review (PBS)


Independent Review of the Impact of PBS Cost Recovery


Working together to improve the Pharmaceutical Benefits Scheme: Review of Post PBAC Processes Report (2004)

Top of page